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INTRODUCTION
Breast cancer is the most frequently diagnosed cancer in 
women worldwide [1]. Even though it remains the second 
most common cause of cancer deaths [1], survival outcomes 
have improved in patients with breast cancer. The advances in 
molecular biology have contributed to the recent survival im-
provement, in addition to the widespread use of breast screen-
ing programs and new drugs such as anthracyclines and tax-
anes in chemotherapy [2,3].
The recent advances in cancer genomics have led to the elu-
cidation of the intrinsic subtypes of breast cancer, thereby re-
sulting in the delivery of target therapies including endocrine 
therapy and anti-human epidermal growth factor receptor 2 
(HER2) therapy for appropriate patients with breast cancer 
who have hormone receptor (HR)-positive or HER2-positive 
tumors [2,4,5]. The success of targeted therapies has been in-
tegral to the improved treatment outcome in patients with 
breast cancer. Conversely, nonspecific chemotherapy remains 
the mainstay for the management of patients with triple-nega-
tive breast cancer (TNBC), which lacks the expression of three 
cellular receptors: estrogen receptor (ER), progesterone recep-
tor, and HER2. TNBC, which accounts for 15% to 20% of the 
cases of invasive breast cancer, is usually aggressive, with 
higher grades or frequent nodal metastasis, and usually devel-
ops at a higher rate in young patients [6,7]. Patients with 
TNBC tend to experience an increased likelihood of distant 
metastasis and early recurrence in 2 or 3 years after treatment, 
compared with patients with other subtypes of breast cancer; 
patients with TNBC also tend to have lower survival [6,7]. 
By adopting unsupervised clustering analyses with genomic 
data of cases of TNBC, several subtypes of TNBC have been 
identified over the years [8-11]. These studies have shown that 
TNBC is remarkably heterogeneous at the transcriptional lev-
el. They further revealed that TNBC could be classified into 
several subtypes, with unique biological pathways for each 
subtype. This molecular heterogeneity of TNBC has been the 
main barrier in improving survival and in developing targeted 
therapy for patients with TNBC. Therefore, to deliver person-
alized therapy for patients with TNBC, researchers have pri-
oritized the development of a standardized method of subtyp-
ing. Herein, by reviewing previous genomic studies about the 
classifications of TNBC, we highlighted the unmet need for 
the development of a molecular classifier for TNBC.
TNBC SUBTYPES BY GENE EXPRESSION 
ANALYSES
The Vanderbilt subtype
In the last decade, there has been intensive research to iden-
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tify therapeutic targets for TNBC based on genomics. Since 
Perou et al. [12] published their landmark study categorizing 
breast cancer by gene expression profiling into intrinsic sub-
types, gene expression profiling analyses have been widely ad-
opted in classifying and discovering relevant therapeutic tar-
gets among the various methods using genomic data. An early 
study using gene expression profiles from TNBC reported 
that triple-negative tumors are synonymous with basal-like 
cancer, although five distinct subgroups are observed on hier-
archical analysis [9]. 
In 2011, the researchers of the Vanderbilt University report-
ed a seminal study classifying TNBC into distinct subtypes [8]. 
Using gene expression analyses from 587 TNBC tumors, they 
illustrated that TNBC consists of six distinguished subtypes 
and displays a unique biology that responds differently to vari-
ous therapies. By k-means and consensus clustering, they 
found the following six subtypes: two basal-like subtypes, one 
with increased cell cycle and DNA damage response gene sig-
natures (BL1) and the other one with high expression growth 
factor pathway and myoepithelial markers (BL2); two mesen-
chymal subtypes with up-regulated gene signatures associated 
with cell differentiation and growth factor signaling (M and 
MSL); an immunomodulatory (IM) type with enriched im-
mune cell processes; and a luminal androgen subtype charac-
terized by androgen signaling (LAR). They found that distinct 
gene ontologies are involved with each TNBC subtype as brief-
ly described above. Furthermore, they identified TNBC cell 
lines representing these subtypes by using gene expression 
analysis. They generated preclinical evidence for the clinical 
application of TNBC subtyping by correlating driver signaling 
pathways with the results of in vitro drug response assays using 
pharmacologically targeted treatment, offering distinct gene 
signatures that could forecast an effective tailored treatment. 
These experiments showed that DNA damaging agents such as 
cisplatin are effective for the basal-like subtype, NVP-BEZ335 
as an mammalian target of rapamycin (mTOR)-phosphati-
dylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
(PIK3CA) co-inhibitor for the mesenchymal subtype, and bi-
calutamide as an androgen receptor (AR) blockade for the 
LAR subtype. 
Comparisons between the Vanderbilt subtype and the PAM50 
subtype
Among 374 of the 587 cases of TNBC used for molecular 
subtyping in the Vanderbilt study, the PAM50 intrinsic sub-
types were directly compared with the TNBC subtypes [13]. 
As expected, most TNBC samples were classified into the bas-
al-like subtype by PAM50 (80.6%). The HER2-enriched in-
trinsic subtype was the second most common subtype 
(10.2%), followed by the normal-like (4.6%), luminal B (3.5%), 
and luminal A (1.1%) subtypes by PAM50. Considering the 
Vanderbilt subtypes, most subtypes are composed of the bas-
al-like PAM50 subtype, except for the MSL and LAR sub-
types. In the MSL subtype, half of the cases were basal-like, 
and the other half consisted of the normal-like (27.8%) and 
luminal B (13.9%) subtypes. In contrast, the LAR subtype 
mainly consists of the HER2 (74.3%) and luminal B (14.3%) 
subtype by PAM50 subtyping. This comparison suggests that 
PAM50-based subtyping alone has the potential to identify 
approximately 75% of the LAR subtype when PAM50 assay 
indicates the HER2-intrinsic subtype. 
Validation of the Vanderbilt subtypes
To test the clinical usefulness of the Vanderbilt subtype, re-
searchers developed an online tool (TNBCtype) to classify the 
molecular subtypes of TNBC using raw data of gene expres-
sion profiling regardless of array platforms [14]. In 2013, Masuda 
et al. [15] utilized the subtyping tool and validated the clinical 
correlation of the Vanderbilt subtype in patients with TNBC 
who underwent neoadjuvant anthracyclines-taxanes containing 
chemotherapy. In the study by Masuda et al. [15], the overall 
pathologic complete response (pCR) rate was 28%. However, 
pCR rates substantially differed according to the subtypes. 
The highest pCR rate (52%) was observed in the BL1 subtype. 
By contrast, the pCR rate was lower in patients with the BL2, 
MSL, and LAR subtypes (0%, 23%, and 10%, respectively). 
When a likelihood ratio test was applied, the Vanderbilt 
subtype was demonstrated to be a significant factor for pCR 
status. They also validated the TNBC subtyping tool in 163 
TNBC cases from The Cancer Genome Atlas (TCGA) [16]. In 
accordance with the previous work by Masuda et al. [15], the 
study by Abramson et al. [16] showed a similar proportion of 
the Vanderbilt subtypes and different survival outcome by the 
subtypes.
The working group of the Gangnam Severance Hospital also 
used the TNBCtype [14] and identified their own subtypes by 
uploading gene expression profiles of 62 Korean TNBC sam-
ples. They previously reported their analyses using gene ex-
pression profiling from 300 Korean breast cancer samples [17]. 
Among the 62 TNBC samples, except for 17 unspecified sub-
types, the other cases were classified as eight BL1 (17.8%), eight 
BL2 (17.8%), 11 IM (24.4%), nine LAR (20.0%), seven M 
(15.5%), and two MSL subtypes (4.5%) (Figure 1). The distri-
bution of the Vanderbilt subtypes in their data was similar to 
the results of the previous study [8], and indicates that this sub-
typing can be utilized for Korean patients with TNBC. 
Even though there remains an unmet need for prospective 
validation of the Vanderbilt subtype in patients with TNBC, 
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these findings showed that the Vanderbilt subtype guides the 
identification of the molecular subtype of TNBC, which may 
lead to subtype-driven chemotherapy or targeted therapy. 
The Baylor subtype
In 2014, there was another classifier of TNBC proposed by 
the researchers of the Baylor University [10]. By integrating 
mRNA expression and DNA profiling for 198 TNBC tumor 
samples, they tried to classify the molecular subtypes of 
TNBC and discover therapeutic targets for each subtype. Us-
ing the nonnegative matrix factorization method, they discov-
ered classifier panels comprising 80 core genes. They classified 
TNBC tumors into the following four distinct subtypes: (1) 
LAR, (2) mesenchymal (MES), (3) basal-like immunosup-
pressed (BLIS), and (4) basal-like immune-activated (BLIA). 
Among all the subtypes, tumors with the BLIS subtype 
showed the worst prognosis, while tumors with the BLIA sub-
type showed the best prognosis. 
The researchers performed a direct comparison between 
the Baylor subtype and the Vanderbilt subtype. They observed 
that the LAR subtype of the Baylor classifier was identical to 
the LAR subtype of the Vanderbilt classifier. In addition, most 
cases of the MES subtype contained the MSL and M subtypes 
according to the Vanderbilt classifier. However, there was dis-
cordance between the BL1, BL2, and IM subtypes by the 
Vanderbilt classifier with those of the Baylor subtype. Tumors 
with the BL1 and BL2 subtypes are distributed across BLIS 
and BLIA, while tumors with the IM subtype were classified 
as MES and BLIA. Their subtyping was validated in seven 
public datasets of gene expression profiles from TNBC.
When the Baylor subtype was compared with the PAM50 
intrinsic subtype, BLIS and BLIA consisted of only the basal-
like subtype. The MES subtype was separated into two PAM50 
intrinsic subtypes: the basal-like and normal-like subtypes. 
Interestingly, the LAR subtype of the Baylor classifier was 
composed of the basal-like, luminal A, luminal B, HER2-en-
riched, and normal-like subtypes by PAM50, indicating the 
heterogeneity of the LAR subtype. 
Furthermore, DNA copy number profiling separates the 
Baylor subtype into two major groups: LAR versus MES/
BLIS/BLIA. The researchers suggested therapeutic candidates 
for specific subtypes: (1) targeting the AR and cell surface mu-
cin (MUC1) for the LAR subtype; (2) inhibiting growth factor 
signaling such as platelet-derived growth factor (PDGF) re-
ceptor A and c-Kit, for the MES subtype; (3) inhibiting an im-
munosuppressing molecule such as V-set domain containing 
T cell activation inhibitor 1 (VTCN1) for the BLIS subtype; 
and (4) targeting stat signal transduction molecules and cyto-
kines for the BLIA subtype.
The researchers concluded that TNBC could be classified 
into four distinct subtypes with different prognoses. In agree-
ment with the Vanderbilt study, they also concluded that tar-
Figure 1. Distributions of the Vanderbilt subtypes using TNBCtype in Korean women with triple-negative breast cancer (n=45). 
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geted therapy for TNBC subtypes is possible in the future for 
more effective and tailored management. 
The French subtype
The researchers of the Unicancer center in France reported 
another subtyping method for TNBC [11]. Similar to earlier 
studies on subtyping [8,10], they used gene expression profil-
ing for 194 TNBC samples and adopted fuzzy clustering. They 
discovered three subtypes in the training set (n= 107): C1, lu-
minal AR, 22.4%; C2, basal-like with low immune response 
and high M2-like macrophages, 44.9%; C3, basal-enriched 
with high immune response and low M2-like macrophages, 
32.7%; they validated these subtypes in another cohort 
(n= 87). They found that the tumor grade and the Nottingham 
prognostic index were higher in C2 and C3 than in C1. On 
comparisons of event-free survival, patients with C3 tumors 
had a significantly better outcome compared to patients with 
C1 or C2 tumors. Their functional analyses showed that luminal 
androgen signaling was enriched in C1 tumors, similar to LAR 
in the Vanderbilt and the Baylor classifiers. The C2 type consisted 
of an almost pure basal-like cancer according to the PAM50 
assay. The claudin-low subtype as well as the basal-like type 
was observed in 26% of C3 tumors. Furthermore, immune 
response signaling, which is associated with a high immune 
response and low M2-like macrophage was enriched in C3 
tumors, which has similarities with the IM subtype of the 
Vanderbilt classifier or BLIA of the Baylor classifier. The findings 
highlight that targeting immune response genes and lowering 
macrophages would be an effective therapeutic strategy for 
TNBC. 
Comparison across the three classifiers of TNBC
Despite the pervasive differences in the methodology and 
number of samples, all the three studies provided identical ev-
idence that biological pathways predominantly exist for each 
subtype of TNBC. The similarities and differences across the 
three TNBC classifiers are shown in Table 1. All the studies 
performed unsupervised hierarchical clustering analysis using 
mRNA expression profiles as the initial step. Although core 
classifying gene panels and the number of final subtypes were 
different across the three studies, all the studies had four ma-
jor subtypes: basal, mesenchymal, LAR, and IM. Owing to tu-
mor heterogeneity, basal-like cancer comprised a large pro-
portion of cases of TNBC. Tumors with enriched immune 
signaling or luminal androgen pathway were commonly noted 
across all the three classifiers. Even though the French study 
did not distinguish the mesenchymal subtype from the other 
TNBC subtypes, the Vanderbilt and the Baylor studies differ-
entially identified subtypes with enriched mesenchymal fea-
tures. We summarized emerging therapeutic strategies for 
each major molecular subtype in Table 2.
Four major classes of TNBC
Basal-like subtype
In basal-like subtype tumors, the biological pathways in-
volving cell cycle and DNA damage response (e.g., ATR/BRCA) 
are highly activated, accelerating cell proliferation [8]. Therefore, 
targeting DNA damage response pathways could be an effec-
tive therapeutic approach. Two agents have been emerging as 
target drugs for tumors with DNA damage response path-
ways, such as platinum salt and poly ADP-ribose polymerase 
1 (PARP) inhibitors [18]. In those tumor cells, there are de-
Table 1. Comparisons across three molecular classifications in triple-negative breast cancer    
Author Year of publication Data set No. of patients Method Subtype no. Prognostic discrimination
Lehmann et al. [8] 2011 Public 586 K-means clustering 6 Poorly
Burstein et al. [10]  2014 Single institute 198 NMF 4 Well
Jézéquel et al. [11] 2015 Single institute 194 Fuzzy clustering 3 Well
NMF=non-negative matrix factorization.
Table 2. Promising subtype-directed personalized therapy in triple-negative breast cancer 
Basal-like Mesenchymal Immune Luminal androgen
Biologic pathway DNA damage response EMT signaling Immune cell signaling Luminal androgen signaling
Cell cycle pathway Wnt signaling
Notch signaling
Promising therapy Platinum MET inhibitor Immune checkpoint inhibitor Androgen blockade
PARP inhibitor FGFR inhibitor PIK3CA inhibitor
mTOR inhibitor
EMT=epithelial-to-mesenchymal transition; MET=met tyrosine kinase; PARP=poly ADP-ribose polymerase; FGFR=fibroblast growth factor receptors; 
PIK3CA=phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; mTOR=mammalian target of rapamcyin.
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fects in the homologous recombination repair system, which 
are vulnerable to platinum salts or PARP inhibitors that lead 
to DNA cross-link strand breaks.
Platinum salts have been mainly tested as neoadjuvant 
treatment for TNBC. Recent large phase II studies provided 
promising results regarding the activity of platinum salts for 
TNBC. The GeparSixto trial compared paclitaxel, doxorubi-
cin, and bevacizumab with (n= 159) or without (n= 161) car-
boplatin as neoadjuvant treatment [19]. The pCR rate was sig-
nificantly higher in patients treated with carboplatin (58.7%) 
than in patients treated without carboplatin (37.9%). Another 
study, CALGB40603, tested the addition of carboplatin or 
bevacizumab to backbone chemotherapy of weekly paclitaxel 
followed by dose-dense doxorubicin-cyclophosphamide as 
neoadjuvant treatment for patients with TNBC [20]. The pCR 
rate was also higher in women treated with carboplatin (54%) 
than in women treated without carboplatin (41%). Apart from 
the pCR rates, further results regarding survival outcomes are 
needed from both studies.
Platinum agents have also been tested for the treatment of 
metastatic TNBC. A phase III trial, the CBCSG006 study 
showed that cisplatin in addition to gemcitabine could be an 
alternative or the preferred first-line option for metastatic 
TNBC compared with paclitaxel plus gemcitabine [21]. The 
progression-free survival was 7.73 months in patients treated 
with cisplatin (n= 120) and 6.47 months in patients treated 
with paclitaxel (n= 120). A significant difference was found in 
both the noninferiority and superiority tests. 
Another phase III trial, the TNT study compared carbopla-
tin monotherapy with docetaxel monotherapy for patients 
with metastatic or recurrent locally advanced triple-negative 
or BRCA1/2 breast cancer [22]. The primary end-point was 
the objective response rate (ORR). The ORR was not signifi-
cantly different between the two groups: 31.4% in patients 
treated with carboplatin (n = 188) versus 35.6% in patients 
treated with docetaxel (n= 188). However, the ORR of carbo-
platin was significantly higher than that of docetaxel in wom-
en with BRCA1/2 mutation (68.0% vs. 33.3%, respectively). 
The superiority of carboplatin to docetaxel considering the 
ORR was not found in patients without BRCA1/2 mutation. 
The observation of superior response to cisplatin in BRCA1/2 
carriers implies that BRCA1/2 germline mutations can be pre-
dictive for platinum treatment. 
Inconsistent results from those studies testing platinum 
agents in patients with TNBC may be associated with the fact 
that patients with non-basal-like tumors according to the 
Vanderbilt classifier may still be included in the study popula-
tions. Non-basal-like tumors occupying near half of TNBC 
have been a confounding component to identify the true ben-
efit of platinum agents for patients with basal-like tumors. 
Further analyses excluding non-basal-like tumors by the 
Vanderbilt subtype in these studies will be needed to exactly 
evaluate the clinical benefit of platinum agents for patients 
with basal-like tumors.
PARP inhibitors—as a target agent for DNA repair sys-
tems—are also promising drugs for basal-like tumors. Despite 
the failure of iniparib in a phase III study [23], a new class of 
PARP inhibitors including olaparib and rucaparib has been 
tested in ongoing trials. Findings from earlier studies highlight 
the importance of predictive biomarkers for PARP inhibitors. 
In addition to germline BRCA mutations, biomarkers associ-
ated with BRCAness have been developed. For this purpose, 
the homologous recombination deficiency (HRD) score was 
also adopted to identify tumors with BRCAness, which has a 
homologous recombinant pathway deficiency [18]. In add-
ition, the BRCA1 methylation status can be a potential marker 
associated with BRCAness [24,25]. To understand the clinical 
response rate of agents targeting the DNA repair system, pre-
dictive biomarkers are urgently needed.
Mesenchymal subtype
Diverse biological processes are enriched in tumors with 
the mesenchymal subtype. Genomic data suggested that gene 
clusters involving cell motility, extracellular matrix interac-
tion, epithelial-to-mesenchymal transition (EMT), and 
growth factor signaling pathways contribute to the unique 
features of mesenchymal tumors. Interestingly, more than half 
of metaplastic carcinoma cases are classified into mesenchy-
mal tumors (16 of 28; 57.1%) according to the histology [26]. 
To treat mesenchymal-like tumors, various therapeutic 
approaches have been evaluated owing to the heterogeneity 
of TNBC. In a previous study with the Vanderbilt subtype, 
Lehmann et al. [8] proposed that mesenchymal-like TNBC 
may be sensitive to mTOR inhibitors such as NVP-BEZ235 
because these cancer cells have activated PI3K/AKT signaling 
owing to PIK3CA mutations or PTEN deficiency. In addition, 
eribulin mesylate, which significantly suppress the EMT path-
way in breast cancer cells, may be another treatment option for 
mesenchymal-like tumors [27]. For targeting the EMT path-
way, it is evident that inhibition of the fibroblast growth factor 
receptor pathway can be actionable in these tumors [28,29].
Immune-enriched subtype
The IM subtype is characterized as tumors that have en-
riched genes involving immune cell processes. Gene enrich-
ment associated with immune cell signaling is a common 
characteristic in the IM subtype in the Vanderbilt classifier [8], 
BLIA in the Baylor classifier [10], and C3 in the French classi-
228  Sung Gwe Ahn, et al.
http://ejbc.kr http://dx.doi.org/10.4048/jbc.2016.19.3.223
fier [11]. Enriched gene clusters of the IM subtype include 
immune cell signaling associated with T cells, B cells, NK cells, 
and dendritic cells; antigen presentation signaling; cytokine 
signaling; and immune signal transduction such as NF-κB, 
JAK/STAT, and tumor necrotic factor (TNF) signaling. Con-
sidering distinct histologic phenotype such as lymphocytic 
infiltrations in stromal tissue, medullary carcinoma may be 
classified into this molecular subtype. Using the current treat-
ments with cytotoxic chemotherapy, patients with the IM 
subtype showed a better treatment outcome compared with 
patients with other subtypes. However, it is unclear whether 
patients with the IM subtype may derive more benefits from 
immune checkpoint blockade, and ongoing studies with this 
type of immune drugs will answer this.
Luminal AR subtype
The LAR subtype is the most distinct subtype. In these tu-
mors, hormone regulation pathways and estrogen/androgen 
metabolism pathways are expressed differentially compared 
to tumors with the other subtypes. In addition, DNA copy 
number analysis by Burstein et al. [10] revealed that LAR tu-
mors are biologically distinguished from other subtypes. For 
tumors with the LAR subtype, an approach for luminal an-
drogen blockade has a theoretical priority owing to its unique 
biological pathway, as this will aid in developing targeted ther-
apy for LAR tumors.
Gucalp et al. [30] reported a phase II trial evaluating the 
clinical benefit of bicalutamide, an AR blocker, in patients 
with AR-positive TNBC. In 51 of 424 AR-positive patients 
(12%), the clinical benefit rate (CBR) was 19%, and supported 
the concept that androgen blockade is clinically actionable in 
AR-positive TNBC.
In the 2015 annual meeting of the American Society of 
Clinical Oncology, researchers presented the results of a phase 
II study of enzalutamide, another AR inhibitor, in advanced 
AR-positive TNBC [31]. In 75 patients with AR-positive 
TNBC (AR ≥ 10%), the CBR was 35%. In addition, the CBR 
was 39% for 56 patients with positive molecular AR-signa-
tures, whereas it was 11% for 62 patients with negative signa-
tures. These two studies provide clinical evidence that AR 
blockade may offer a clinical benefit for patients with AR-pos-
itive TNBC. 
Furthermore, Lehmann et al. [32] suggested that PI3K in-
hibitors in addition to an AR antagonist would be more effec-
tive in treating AR-positive TNBC because PIK3CA mutations 
are frequently activated in these tumors. Further studies test-
ing the clinical effect of concurrent treatment of PI3K inhibi-
tors and AR blockades are warranted in future. 
PROGNOSTIC DIFFERENTIATION
In terms of the prognosis, survival differences according to 
the molecular subtypes are pronounced in the Baylor and the 
French studies, but not in the Vanderbilt study. All the three 
studies agree that the patients with immune-enriched subtype 
have the best survival outcomes. Conversely, for patients with 
the LAR subtype, the survival outcome was the worst in the 
French study. In the last two studies, the mesenchymal type or 
BLIS showed the worst outcomes. Thus, there is a discrepancy 
in predicting the prognosis according to the molecular sub-
types of TNBC. 
PERSPECTIVES AND FUTURE DIRECTION
As these studies exemplified, there are efforts in classifying 
TNBC by gene expression profiling with biologic relevance. 
Despite the discrepancy in the number of subtypes or the clas-
sifying methods, all the studies suggested that TNBC consists 
of several subtypes and may require subtype-specific therapy 
based on their biological characteristics. All these studies with 
molecular classifications provide sufficient evidence that there 
are four major subtypes, indicating the need for subtype-tar-
geted therapy for TNBC.
In addition, a single biomarker has inherit limitations; for in-
stance, the HRD score only identifies tumor with homologous 
recombinant deficiency that may be treated with DNA damage 
response targeting drugs, while tumors with a low HRD score 
remain a group without targeted therapy. The molecular diver-
sity of TNBC cannot be dissected by a single biomarker. 
CONCLUSION
In conclusion, to deliver optimizing therapies for most pa-
tients with TNBC, a comprehensive classification is necessary 
based on genomic data. This type of classifier will offer oppor-
tunities for both subtyping and subtype-guided therapy in pa-
tients with TNBC. In the near future, the subtypes of TNBC 
would be easily identified that, in conjunction with clinically 
available classifiers, will help advance the management of 
women with TNBC.
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